All
  • All
  • Insight
  • Research Services
  • Preclinical CRO
  • Animal Resource Bank
CN
中文 English
Best-selling laboratory mouse strains

Related Resources

Resource Center

APP/PS1 mouse littermate control

Jiangsu Aniphe BioLabtechnology offers in‑litter control resources using APP/PS1 double-transgenic mice, managed strictly according to standardized breeding protocols and verified by genotyping to ensure the reliability of the control animals’ origins. By providing age-, sex-, and genetic background–matched littermate negative controls, this approach effectively minimizes the impact of individual variability on experimental outcomes, thereby establishing a stable and reliable experimental foundation for Alzheimer’s disease model studies, drug efficacy evaluations, and mechanistic analyses.

Strain Introduction

APP/PS1 double-transgenic mice (commonly designated as APPswe/PSEN1dE9) constitute a classic model of Alzheimer’s disease (AD). By co‑expressing the human APP Swedish mutation (K670N/M671L) and a PSEN1 exon 9 deletion mutation (ΔE9) in CNS neurons, this model exhibits excessive Aβ production and age‑dependent extracellular plaque deposition. It serves as a principal model for investigating the Aβ cascade hypothesis and for evaluating anti‑amyloid therapies.

Source of litter-mate controls: Non‑transgenic pups born to the same litter (−/−), with a genetic background identical to that of the transgenic mice (C57BL/6; C3H mixed background), were used as ideal controls to eliminate confounding effects attributable to genetic background, maternal environment, and housing conditions.

Product Advantages

Data parameters

Strain Name

APPswe/PSEN1dE9 double-transgenic mice (commonly abbreviated as APP/PS1)
Targeted gene

Human APP, human PSEN1
Mutation site

APP: K670N/M671L (Swedish) PSEN1: Exon 9 deletion (ΔE9)
Types of gene editing

Random integration transgenics (driven by the PrP or PDGFβ promoter, typically generated via co-injection; the JAX strain uses the Prnp promoter)
Genetic background

C57BL/6J × C3H/HeJ hybrid background (JAX #005864, etc.; some lines have been backcrossed to a C57BL/6 background)
Microbial Grade

SPF grade
Fur color

Brownish-brown, black
Gender

Female/Male
Available by week of age

3 weeks of age and older

Application areas

Breeding Techniques and Precautions

Strictly control inbreeding systems to mitigate genetic divergence.

 

Breeding strategy: We recommend mating hemizygous male mice (Tg/+) with wild-type female mice (+/+). This approach yields both transgenic mice and WT controls within the same litter, thereby eliminating the need for commercially sourced controls. Homozygous breeding is strictly prohibited, as homozygotes are often lethal or exhibit severely compromised phenotypes.

 

Strictly control environmental stimuli to reduce experimental stress.

 

Before randomizing animals into experimental groups, it is essential to house transgenic and wild-type mice from the same litter together in separate individually ventilated cages (IVCs) to prevent microbiota and metabolic differences arising from cage‑box effects.

Literature support

Frequently Asked Questions

Image Name

Q1: Why must we use littermate wild-type (WT) mice as controls, rather than purchasing C57BL/6 mice separately?

Image Name

A: The APP/PS1 mouse strain typically has a C57BL/6;C3H genetic background, and even after prolonged backcrossing, residual donor‑derived genomic segments may persist. Moreover, maternal effects and the gut microbiota—among other microenvironmental factors—can influence the AD phenotype. Only wild‑type mice from the same litter can ensure complete concordance in genetic background and housing history, thereby eliminating these confounding variables and establishing the gold standard for phenotypic and pharmacological analyses.

Image Name

Q2: In APP/PS1 mice, in which brain regions do amyloid plaques primarily accumulate, and when do they first become detectable?

Image Name

A: Sporadic plaques can first be detected in the cortex and hippocampus at 4 months of age, with rapid expansion by 6 months; concurrently, they also begin to appear in the thalamus and striatum. Cerebral amyloid angiopathy (CAA) is a hallmark of this model and can be leveraged for studies of vascular pathology.

Image Name

Q3: Does this model exhibit tau pathology and neuronal loss?

Image Name

A: In APP/PS1 mice, mature neurofibrillary tangles are generally absent; however, elevated levels of phosphorylated tau are observed, associated with dystrophic neurites surrounding amyloid plaques. After 6 months of age, focal neuronal loss can be detected in areas with dense plaque deposition, though the overall extent of neuronal loss is less pronounced than in the 5×FAD model.

More models